Powered by: Motilal Oswal
2026-09-22 12:42:52 pm | Source: Accord Fintech
Anlon Healthcare shines on incorporating subsidiary in Nigeria
Anlon Healthcare shines on incorporating subsidiary in Nigeria

Anlon Healthcare is currently trading at Rs. 29.02, up by 2.62 points or 9.92% from its previous closing of Rs. 26.40 on the BSE.

The scrip opened at Rs. 27.45 and has touched a high and low of Rs. 29.04 and Rs. 26.92 respectively. So far 10206876 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 29.04 on 22-Sep-2026 and a 52 week low of Rs. 10.28 on 02-Mar-2026.

Last one week high and low of the scrip stood at Rs. 29.04 and Rs. 19.60 respectively. The current market cap of the company is Rs. 1543.52 crore.

The promoters holding in the company stood at 52.68%, while Institutions and Non-Institutions held 2.89% and 44.43% respectively.

Anlon Healthcare has incorporated a subsidiary namely ‘Anlon Healthcare Nigeria’ in Nigeria on September 20, 2026. The purpose of incorporation of this subsidiary is aligned with the company’s long-term growth objective. Considering this subsidiary would be manufacturing, importing, processing, producing, trading, packaging, selling, blending, making of Active Pharmaceutical Ingredients (APIs), pharmaceutical bulk drugs, intermediates and Finished Dosage Formulations for human use, cosmetic and personal care products, surgical implants and medical devices. The company intends to leverage this opportunity in order to strategically complement and expand its existing business in the West African market. This subsidiary will provide access to 16 Western African Countries via its local entity.

The company holds 90% of the share capital of Anlon Healthcare Nigeria i.e. 90 million equity shares of face value Naira 1 each of the subsidiary company.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here